Abstract

DESIGN AND IN VITRO CHARACTERIZATION OF PHASE TRANSITION SYSTEM USING RIVASTIGMINE TARTRATE FOR NASAL DRUG DELIVERY SYSTEM

Dr. Chetan Y. Kadam*, Nishan N. Bobade, Paras B. Pophalkar, Sachin U. Hole, Rajnandni S. Suroshe and Wrushali A. Panchale

Abstract

The aim of the present study is to overcome the limitations of nasal cavity like low residence time by using in situ gel forming nasal drug delivery system prepared from polymers that exhibit phase transition (Sol-Gel) and pseudo plastic behaviour to minimize interference within the mucociliary clearance. It the increasing of the delivery residence of the delivery system and enhancing bioavailability. Rivastigmine tartrate, a preferential-type central acting anti-cholinesterase, is currently used in the treatment of Parkinson. Rivastigmine tartrate is readily absorbed from gastrointestinal tract from conventional preparations and crosses the blood brain barrier. It undergoes extensive first pass metabolism in liver. With the advent of new era of pharmaceutical dosage forms, nasal drug delivery system has established itself as an integral part of novel drug delivery system. Nasal gel is prepared by using gelling agent such as Chitosan HCL, HPMC K4M, Carbopol 934, Sodium alginate, Gellun gum and Sod. β-Glycerophosphate and other excipients. It was observed that Phase transition system has best fitted to peppas model. Phase transition nasal gel has r2 value (0.9343) and n value (1.1566). Also, it was observed that nasal gel FF9 a formulation has best fitted to order release. Hence revealed that FF9 optimized formulation.

Keywords: Rivastigmine tartrate, Chitosan HCL, Sod. ?-Glycerophosphate, Sodium alginate.